We’re a different kind of global biopharmaceutical company.
Discover more
Nine consecutive quarters of growth in Q1 2025 with key innovative medicines growing ~40%; 2025 profit outlook improved
Teva has been committed to supporting people with neurological conditions for over 30 years. Hear about the latest innovative advancements from our global medical experts.
Amalia Adler-Waxman, SVP Head of Sustainability at Teva, indicates the key trends in this area.